See the published version of this article at Lipids in Health and Disease.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Małgorzata Moszak
Uniwersytet Medyczny imienia Karola Marcinkowskiego w Poznaniu
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8965-6123
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Lipids in Health and Disease.
Background: Amaranth seed oil (ASO) and rapeseed oil (RSO) are representative functional food with glucose and cholesterol-lowering, antioxidant, and hepatoprotective properties. We aimed to determine whether compared to RSO, ASO supplementation can improve the weight loss and metabolic parameters when consumed as a part of a 3-week weight loss program.
Methods: Eighty-one obese subjects (BMI > 30 kg/m 2 ) aged 25−70 years enrolled in a 3-week body mass reduction program based on calorie-restricted diet and physical activity. The participants were randomly administered 20 ml/d of ASO (AO group) or 20 ml/d of RSO (RO group), or were assigned to the control (C) group. Anthropometric and metabolic parameters were measured at baseline and at endpoint.
Results: At the end of the study, significant ( P < 0.05) decrease in weight, BMI, WC (waist circumference), HC (hip circumference), FM (fat mass), LBM (lean body mass), VFM (visceral fat mass), and TBW% (total body water) were observed in all the studied groups. There were no significant improvements in clinical parameters in the C group, while reduction in fasting insulin ( P = 0.001 and P = 0.005) and HOMA-IR ( P = 0.02 and P = 0.03) were observed in the RO and AO groups. Compared to the RO group, we observed significant improvement in fasting glucose ( P = 0.03), total cholesterol ( P = 0.03), non-HDL cholesterol ( P = 0.01), TG/HDL ratio ( P = 0.03), LDL cholesterol ( P = 0.04), and triglycerides ( P = 0.000008) in the AO group.
Conclusions: The 3-week body mass reduction intervention resulted in statistically significant reduction in weight, BMI, WC, HC, FM, and VFM in all the studied groups. The fasting insulin level and HOMA-IR improved in both AO and RO groups. In contrast to the RO group, positive changes in glucose and lipid levels were observed in the AO group. Compared to the AO and RO groups, subjects without oil supplementation did not show improvement in clinical parameters. Thus, edible oils may improve metabolic parameters during weight loss programs.
Keywords
Amaranth seed oil, Body composition, Metabolic profile, Rapeseed oil, Weight loss
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Published
On 20 Jun, 2020
No community comments so far
Editor assigned
On 15 Jun, 2020
Reviewers invited
Invitations sent on 15 Jun, 2020
Submission checks complete
On 14 Jun, 2020
Editor invited
On 14 Jun, 2020
No comments provided
Editor assigned
On 11 Jun, 2020
Editorial decision: Major revision
On 11 Jun, 2020
Submission checks complete
On 10 Jun, 2020
Editor invited
On 10 Jun, 2020
No comments provided
Review #5 received
Received 30 May, 2020
Editorial decision: Major revision
On 30 May, 2020
Review #3 received
Received 26 May, 2020
Review #2 received
Received 26 May, 2020
Reviewer #5 agreed
On 23 May, 2020
Reviewer #4 agreed
On 20 May, 2020
Review #4 received
Received 20 May, 2020
Editor assigned
On 19 May, 2020
Reviewers invited
Invitations sent on 19 May, 2020
Reviewer #1 agreed
On 19 May, 2020
Reviewer #2 agreed
On 19 May, 2020
Review #1 received
Received 19 May, 2020
Reviewer #3 agreed
On 19 May, 2020
Submission checks complete
On 18 May, 2020
Editor invited
On 18 May, 2020
Version 1
Posted 05 Feb, 2020
No comments provided
Editorial decision: Major revision
On 30 Apr, 2020
Review #5 received
Received 29 Apr, 2020
Review #3 received
Received 22 Apr, 2020
Review #2 received
Received 15 Apr, 2020
Review #4 received
Received 12 Apr, 2020
Reviewer #5 agreed
On 07 Apr, 2020
Reviewer #4 agreed
On 05 Apr, 2020
Reviewer #3 agreed
On 03 Apr, 2020
Reviewer #2 agreed
On 01 Apr, 2020
Reviewer #1 agreed
On 31 Mar, 2020
Review #1 received
Received 31 Mar, 2020
Reviewers invited
Invitations sent on 30 Mar, 2020
Editor assigned
On 29 Jan, 2020
Submission checks complete
On 28 Jan, 2020
Editor invited
On 28 Jan, 2020
First submitted
On 26 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at Lipids in Health and Disease. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Małgorzata Moszak
Uniwersytet Medyczny imienia Karola Marcinkowskiego w Poznaniu
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8965-6123
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
Published
On 20 Jun, 2020
No community comments so far
Editor assigned
On 15 Jun, 2020
Reviewers invited
Invitations sent on 15 Jun, 2020
Submission checks complete
On 14 Jun, 2020
Editor invited
On 14 Jun, 2020
No comments provided
Editor assigned
On 11 Jun, 2020
Editorial decision: Major revision
On 11 Jun, 2020
Submission checks complete
On 10 Jun, 2020
Editor invited
On 10 Jun, 2020
No comments provided
Review #5 received
Received 30 May, 2020
Editorial decision: Major revision
On 30 May, 2020
Review #3 received
Received 26 May, 2020
Review #2 received
Received 26 May, 2020
Reviewer #5 agreed
On 23 May, 2020
Reviewer #4 agreed
On 20 May, 2020
Review #4 received
Received 20 May, 2020
Editor assigned
On 19 May, 2020
Reviewers invited
Invitations sent on 19 May, 2020
Reviewer #1 agreed
On 19 May, 2020
Reviewer #2 agreed
On 19 May, 2020
Review #1 received
Received 19 May, 2020
Reviewer #3 agreed
On 19 May, 2020
Submission checks complete
On 18 May, 2020
Editor invited
On 18 May, 2020
Version 1
Posted 05 Feb, 2020
No comments provided
Editorial decision: Major revision
On 30 Apr, 2020
Review #5 received
Received 29 Apr, 2020
Review #3 received
Received 22 Apr, 2020
Review #2 received
Received 15 Apr, 2020
Review #4 received
Received 12 Apr, 2020
Reviewer #5 agreed
On 07 Apr, 2020
Reviewer #4 agreed
On 05 Apr, 2020
Reviewer #3 agreed
On 03 Apr, 2020
Reviewer #2 agreed
On 01 Apr, 2020
Reviewer #1 agreed
On 31 Mar, 2020
Review #1 received
Received 31 Mar, 2020
Reviewers invited
Invitations sent on 30 Mar, 2020
Editor assigned
On 29 Jan, 2020
Submission checks complete
On 28 Jan, 2020
Editor invited
On 28 Jan, 2020
First submitted
On 26 Jan, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Lipids in Health and Disease.
Background: Amaranth seed oil (ASO) and rapeseed oil (RSO) are representative functional food with glucose and cholesterol-lowering, antioxidant, and hepatoprotective properties. We aimed to determine whether compared to RSO, ASO supplementation can improve the weight loss and metabolic parameters when consumed as a part of a 3-week weight loss program.
Methods: Eighty-one obese subjects (BMI > 30 kg/m 2 ) aged 25−70 years enrolled in a 3-week body mass reduction program based on calorie-restricted diet and physical activity. The participants were randomly administered 20 ml/d of ASO (AO group) or 20 ml/d of RSO (RO group), or were assigned to the control (C) group. Anthropometric and metabolic parameters were measured at baseline and at endpoint.
Results: At the end of the study, significant ( P < 0.05) decrease in weight, BMI, WC (waist circumference), HC (hip circumference), FM (fat mass), LBM (lean body mass), VFM (visceral fat mass), and TBW% (total body water) were observed in all the studied groups. There were no significant improvements in clinical parameters in the C group, while reduction in fasting insulin ( P = 0.001 and P = 0.005) and HOMA-IR ( P = 0.02 and P = 0.03) were observed in the RO and AO groups. Compared to the RO group, we observed significant improvement in fasting glucose ( P = 0.03), total cholesterol ( P = 0.03), non-HDL cholesterol ( P = 0.01), TG/HDL ratio ( P = 0.03), LDL cholesterol ( P = 0.04), and triglycerides ( P = 0.000008) in the AO group.
Conclusions: The 3-week body mass reduction intervention resulted in statistically significant reduction in weight, BMI, WC, HC, FM, and VFM in all the studied groups. The fasting insulin level and HOMA-IR improved in both AO and RO groups. In contrast to the RO group, positive changes in glucose and lipid levels were observed in the AO group. Compared to the AO and RO groups, subjects without oil supplementation did not show improvement in clinical parameters. Thus, edible oils may improve metabolic parameters during weight loss programs.
Figure 1
Loading...